Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 4/20 | 0.79 |
| ▸ | CYP11B2 | P19099 | 4/20 | 0.79 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.59 |
| ▸ | KDM1A | O60341 | 1/20 | 0.57 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.57 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.56 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.56 |
| ▸ | CA1 | P00915 | 1/20 | 0.56 |
| ▸ | CA2 | P00918 | 1/20 | 0.56 |
| ▸ | ATM | Q13315 | 1/20 | 0.54 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.52 |
| ▸ | CCNC | P24863 | 1/20 | 0.51 |
| ▸ | CDK8 | P49336 | 1/20 | 0.51 |
| ▸ | CTSA | P10619 | 1/20 | 0.51 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.49 |
| ▸ | XDH | P47989 | 2/20 | 0.49 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1179945 | 0.88 | CYP11B2 (1.00) | CYP11B1CYP11B2MAP4K4CYP1A2CYP3A4 | |
| SCHEMBL3715051 | 0.87 | ATM (0.69) | CYP11B1CYP11B2CYP1A2CYP3A4MKNK1 | |
| SCHEMBL24499480 | 0.86 | MAP4K4 (0.66) | CYP11B1CYP11B2MAP4K4CYP1A2CYP3A4 | |
| SCHEMBL25002964 | 0.86 | CYP11B2 (0.63) | CYP11B1CYP11B2MAP4K4CYP1A2CYP3A4 | |
| SCHEMBL25002936 | 0.85 | CYP11B1 (0.64) | CYP11B1CYP11B2MAP4K4CYP1A2CYP3A4 | |
| SCHEMBL640295 | 0.85 | CYP11B1 (0.60) | CYP11B1CYP11B2MAP4K4CYP1A2CYP3A4 | |
| SCHEMBL3713278 | 0.85 | CYP11B1 (0.64) | CYP11B1CYP11B2MAP4K4CYP1A2CYP3A4 | |
| SCHEMBL25002911 | 0.85 | CYP11B1 (0.64) | CYP11B1CYP11B2MAP4K4CYP1A2CYP3A4 | |
| SCHEMBL640664 | 0.85 | SCN10A (0.67) | CYP11B1CYP11B2MAP4K4CYP1A2CYP3A4 | |
| SCHEMBL4592444 | 0.84 | CYP11B1 (0.62) | CYP11B1CYP11B2MAP4K4MKNK1MKNK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023010192-A1 | N-ACYLHYDRAZONE COMPOUNDS CAPABLE OF INHIBITING NAV1.7 AND/OR NAV1.8, PROCESSES FOR THE PREPARATION THEREOF, COMPOSITIONS, USES, METHODS FOR TREATMENT USING SAME, AND KITS | EUROFARMA LABORATÓRIOS S.A. (BR) | 2023-02-09 | — | — | WO | disclosed |
| WO-2007132179-A2 | THERAPEUTICS COMPRISING PYRIDINIUM DERIVATIVES | UNIVERSITY OF BATH (GB) | 2007-11-22 | — | — | WO | disclosed |
| WO-2007132179-A2 | THERAPEUTICS COMPRISING PYRIDINIUM DERIVATIVES | UNIVERSITY OF BATH (GB) | 2007-11-22 | — | — | WO | disclosed |
| US-20070105810-A1 | THERAPEUTICS | POTTER BARRY V L | 2007-05-10 | — | — | US | disclosed |
| US-20070105810-A1 | THERAPEUTICS | POTTER BARRY V L | 2007-05-10 | — | — | US | disclosed |
| US-20070105810-A1 | THERAPEUTICS | POTTER BARRY V L | 2007-05-10 | — | — | US | disclosed |
| EP-1689714-A2 | THERAPEUTIC USE OF PYRIDINIUM COMPOUNDS TO MODULATE NAADP ACTIVITY | UNIVERSITY OF BATH (GB) | 2006-08-16 | — | — | EP | disclosed |
| WO-2005054198-A2 | THERAPEUTICS USE OF PYRIDINIUM COMPOUNDS TO MODULATE NAADP ACTIVITY | UNIVERSITY OF BATH (GB) | 2005-06-16 | — | — | WO | disclosed |
| US-4886822-A | SIDE EFFECT REDUCTION | KOWA COMPANY, LTD. (JP) | 1989-12-12 | — | — | US | disclosed |
| EP-0286979-A1 | Substituted anilide derivatives | KOWA COMPANY, LTD. (JP) | 1988-10-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105810-A1 | THERAPEUTICS | RYR1, ATP2A1, CACNA1E | CYP11B1 2268/4885CYP11B2 2472/4885MAP4K4 3311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.